

2016 ANNUAL RESULTS & INVESTOR CONFERENCE CALL

Acrux (ASX: ACR) confirms it will release its financial results for the year ended 30 June 2016 on Thursday 25 August 2016.

The Company will discuss its financial results on Thursday 25 August 2016. Investors will need to access the conference call via phone. Details including telephone numbers and conference ID are provided below.

Investor Conference Call details:

Date: Thursday 25 August 2016

Time: 2pm (Australian Eastern Standard Time)

Conference ID: 548 892

Dial-in Details:

Toll Free Dial-in Details: 1800 558 698

Australia: +61 2 9007 3187

New Zealand 0800 453 055

Singapore 800 101 2785

United States 1855 8811 339

United Kingdom 0800 051 8245

A Q&A session will be held following the Company presentation. Shareholders are encouraged to participate by forwarding questions to investor@acrux.com.au in advance of the Conference Call.

Acrux recommends participants dial in at least 5 to 10 minutes prior to commencement of the call. A recording of the call will be made available in the 'Investor Centre' section of the Company website at: <http://www.acrux.com.au/>

For further information, contact

Michael Kotsanis, CEO and Managing Director: 03 8379 0100

Sharon Papworth, CFO and Company Secretary: 03 8379 0100

About Acrux

Acrux (ASX: ACR) is a pharmaceutical company dedicated to developing and commercialising branded and generic topical pharmaceuticals. Incorporated in 1998 and using in house facilities and capabilities, Acrux has successfully developed and licensed a number of pharmaceutical products in the US and Europe using the Patchless Patch™, a fast-drying and invisible topical application technology. Marketed products include Axiron®, Evamist® and Lenzetto®. More recently, in addition to specialty products, Acrux has identified and initiated development of a range of generic products. Acrux is leveraging its on-site laboratories, GMP manufacturing suite, clinical and commercial experience to bring more products to market. Acrux encourages collaboration and is well positioned to discuss partnering and product development.

For further information on Acrux, visit www.acrux.com.au

